EGFR and neoplasm: Given that Treg cells are closely associated with HCC progression47, 48, lnc-EGFR stimulates Treg expansion through EGFR, and the inhibition of EGFR increases the anti-HCC tumour activity of sorafenib49, 50, the only drug approved for HCC therapy, we speculate that the breakdown of this forward-feedback loop by managing lnc-EGFR may improve the efficacy of sorafenib in the treatment of advanced HCC.